April 12 (Reuters) - Prometic Life Sciences Inc:
* PROMETIC PRESENTS NEW PBI-4050 CLINICAL DATA FROM ONGOING ALSTRöM SYNDROME PHASE 2 TRIAL
* PBI-4050 DECREASED INSULIN RESISTANCE IN LIVER
* FAT BIOPSIES FURTHER DEMONSTRATE PBI-4050 CLINICAL ACTIVITY
* CLINICAL ACTIVITY AND TOLERABILITY OF PBI-4050 WERE SUSTAINED WITH PROLONGED TREATMENT Source text for Eikon: Further company coverage:
